Nilay Gandhi, MD
Urology · Woodbridge, VANPI 1861657488
Payments from drug & device makers
Across 272 payments — averaging $4689.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$602K
- Gyrus ACMI, Inc.$331K
- Laborie Medical Technologies Corp.$152K
- Accord Healthcare, Inc.$61K
- Teleflex LLC$43K
- Olympus Corporation Of The Americas$40K
- plus $45K from 28 others
What the payments were for
- Consulting fees$56,81141%
- Speaking & faculty fees$69,26050%
- Travel & lodging$5,3304%
- Food & beverage$6,5745%
- Education$4030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 54 | $601,896 |
| Gyrus ACMI, Inc. | 2 | $331,317 |
| Laborie Medical Technologies Corp. | 19 | $152,395 |
| Accord Healthcare, Inc. | 36 | $61,219 |
| Teleflex LLC | 28 | $42,993 |
| Olympus Corporation Of The Americas | 2 | $40,137 |
| Endo Pharmaceuticals Inc. | 26 | $16,190 |
| AbbVie | 2 | $6,533 |
| Endo USA, Inc. | 4 | $5,587 |
| Ferring Pharmaceuticals Inc. | 5 | $5,552 |
| Boston Scientific | 12 | $5,192 |
| Procept Biorobotics Corporation | 4 | $1,349 |
| Johnson & Johnson | 5 | $1,288 |
| Sun Pharmaceutical Industries Inc. | 8 | $587 |
| Bioprotect Medical, Inc. | 8 | $585 |
| Calyxo, Inc. | 5 | $499 |
| Astellas Pharma US Inc | 8 | $447 |
| Medtronic(2 entities) | 3 | $255 |
| Tolmar Pharmaceuticals, Inc. | 4 | $218 |
| Olympus America Inc. | 8 | $206 |
| Dendreon Pharmaceuticals LLC | 4 | $196 |
| KARL Storz Endoscopy-america | 2 | $175 |
| Coloplast | 5 | $112 |
| Rochester Medical Corporation | 5 | $99 |
| Koelis Inc. | 1 | $89 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $59 |
| Neotract Inc. | 2 | $54 |
| Urogen Pharma, Inc. | 2 | $42 |
| Novartis | 1 | $33 |
| Progenics Pharmaceuticals, Inc. | 1 | $28 |
| Pfizer | 2 | $27 |
| Photocure Inc | 1 | $19 |
| Metuchen Pharmaceuticals | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMCEVI$49,771
- Barrigel$37,665
- XIAFLEX$21,283
- ADSTILADRIN$5,386
- SpaceOAR VUE System - 10mL$4,978
- AquaBeam Robotic System$1,270
- Erleada$1,110
- CVAC Aspiration System$435
- BIOPROTECT BALLOON IMPLANT SYSTEM$397
- INTERSTIM$211
- PROVENGE$144
- UroLift$143
- 09 PROMO FLEX-X FLEX URETEROSCOPE, 7.5F$140
- ELIGARD$125
How this compares
$1,275,410 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 154 | $407,331 |
| XtandiEnzalutamide | 27 | $361,289 |
| YonsaAbiraterone Acet,submicronized | 22 | $215,849 |
| Abiraterone Acetate | 79 | $59,197 |
| Tamsulosin Hcl | 144 | $2,230 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 87 | $1,582 |
| Solifenacin Succinate | 32 | $1,456 |
| Silodosin | 14 | $1,333 |
| Methylprednisolone | 17 | $311 |
| Prednisone | 52 | $144 |
| Ciprofloxacin Hcl | 24 | $77 |
| Diazepam | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $601,896 | $407,331154 claims |
| Astellas Pharma US IncXtandi | $447 | $361,28927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.
Other urology in Woodbridge
- Shawn MarhamatiWoodbridge$130K
- Alok DesaiWoodbridge$18K
- Pratik DesaiWoodbridge$16K
- Inderjit SinghWoodbridge$14K
- Robert GivenVirginia Beach$8.7M
- Michael WilliamsVirginia Beach$2.7M
- Michael FabrizioVirginia Beach$1.6M
- Gregg EureVirginia Beach$1.5M
- Jessica DelongVirginia Beach$644K
- Eugene KramolowskyRichmond$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.